(Total Views: 899)
Posted On: 07/20/2025 2:16:01 PM
Post# of 155732
brenty wrote
This info was published back in December 2024 and we all were understandably elated by these plans. However plans for a clinical study and a clinical study actually performed is not the same. When a potential investor, interested in Alzheimer research, doing his DD looks at our pipeline and finds the field for Phase One filled wouldn't he assume that this phase was actually completed or at least is in process? Yet we don’t know even if the protocol was indeed submitted to the FDA and the Cornell IRB and approved by them? Why?
Quote:
They did share this...
Third, we have finalized the protocol for a pilot study of leronlimab in the treatment of patients with mild to moderate Alzheimer’s disease. That study will take place at Cornell Medical Center in New York and will evaluate an objective neuroradiology primary endpoint that will provide a clear measure of leronlimab’s potential role in treating Alzheimer’s disease. I am pleased to announce the study is now fully funded by an outside foundation, and the protocol will soon be submitted to both the FDA and the Cornell IRB.
This info was published back in December 2024 and we all were understandably elated by these plans. However plans for a clinical study and a clinical study actually performed is not the same. When a potential investor, interested in Alzheimer research, doing his DD looks at our pipeline and finds the field for Phase One filled wouldn't he assume that this phase was actually completed or at least is in process? Yet we don’t know even if the protocol was indeed submitted to the FDA and the Cornell IRB and approved by them? Why?
(6)
(1)
Whatever happens, we have got
Le-Ron-Li-Mab, and they have not.
Le-Ron-Li-Mab, and they have not.
